ClinicalTrials.gov
ClinicalTrials.gov Menu

Validity of ADHD Subtypes Using Neuropsychological Measure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00494819
Recruitment Status : Completed
First Posted : July 2, 2007
Last Update Posted : November 14, 2012
Sponsor:
Information provided by (Responsible Party):
National Taiwan University Hospital

Brief Summary:

Background: Attention-Deficit/Hyperactivity Disorder (ADHD), characterized by inattention, hyperactivity, and impulsivity, is among the most common neuropsychiatric disorders worldwide (5-10% at school age) and in Taiwan (7.5%). The DSM-IV ADHD consists of three subtypes: predominantly Inattentive (ADHD-I), predominantly Hyperactivity/Impulsivity (ADHD-H), and Combined subtypes (ADHD-C). Although the DSM-IV field trials indicate that the current subtypes differ significantly on variables such as age of onset, gender ratio, and level of social and academic impairment, little has been addressed whether the DSM-IV subtypes differ neuropsychologically. Numerous researches have proved that stimulants (methylphenidate is the only stimulant in Taiwan) are the most effective medication in treating ADHD. Although the efficacy of methylphenidate on behavioral measures has been established in Taiwan, there is no information about neuropsychological measures.

Specific Aims:

  1. to validate ADHD subtype by neuropsychological measures; and
  2. to investigate the efficacy of methylphenidate on the improvement of executive functioning among children with ADHD.

Subjects and Methods: Participants will consist of 20 children with ADHD-C, 20 with ADHD-I, 10 with ADHD-H and 50 controls without ADHD in the age range of 7 to 10. The measures include the psychiatric interviews (Chinese K-SADS-E), neuropsychological tests (WISC-III, Cancellation Test, Digit Span, Trail Making Test, CPT, Circle Tracing Test), self-administered rating scale (SNAP-IV), and investigator administered assessment (CGI and Behavior Observation Ratings).

Anticipated Results: We anticipated that children in the ADHD and non-ADHD group will perform differently on the neuropsychological tests with more deficits in neuropsychological functions in the ADHD group. Also, we expected that methylphenidate will improve the performance on the neuropsychological tests and reduce the behavioral symptoms of ADHD children. Subtypes difference in the neuropsychological functions is also expected.


Condition or disease
Attention-deficit/Hyperactivity Disorder

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 122 participants
Observational Model: Case Control
Official Title: Discriminate Validity of ADHD Subtypes Using Neuropsychological Test
Study Start Date : September 2005
Actual Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   7 Years to 10 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
children with ADHD
Criteria

Inclusion Criteria:

  • patients who have clinically diagnosis of DSM-IV ADHD confirmed by the K-SADS-E, are aged 7-10, and have IQ > 80; and who and whose parents consent to this study

Exclusion Criteria:

  • if they have a history of brain injury or epilepsy, visual/auditory deficit or were diagnosed as having motor disorder, obsessive-compulsive disorder, mental retardation, mood disorders, pervasive developmental disorder, or schizophrenia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00494819


Locations
Taiwan
National Taiwan Univeristy Hospital
Taipei, Taiwan, 10002
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Principal Investigator: Susan Shur-Fen Gau, MD, PhD National Taiwan University Hospital & College of Medicine

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT00494819     History of Changes
Other Study ID Numbers: 9461700916
NSC 94-2815-C-002-177-H ( Other Identifier: National Science Council )
First Posted: July 2, 2007    Key Record Dates
Last Update Posted: November 14, 2012
Last Verified: August 2008

Keywords provided by National Taiwan University Hospital:
ADHD, subtype, methylphenidate, neuropsychological measures

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders